BR112017000955A2 - método para determinar tnfr2:fc, método de purificação de tnfr2:fc e composição de tnfr2:fc - Google Patents

método para determinar tnfr2:fc, método de purificação de tnfr2:fc e composição de tnfr2:fc

Info

Publication number
BR112017000955A2
BR112017000955A2 BR112017000955A BR112017000955A BR112017000955A2 BR 112017000955 A2 BR112017000955 A2 BR 112017000955A2 BR 112017000955 A BR112017000955 A BR 112017000955A BR 112017000955 A BR112017000955 A BR 112017000955A BR 112017000955 A2 BR112017000955 A2 BR 112017000955A2
Authority
BR
Brazil
Prior art keywords
tnfr2
determining
composition
purification
tfr2
Prior art date
Application number
BR112017000955A
Other languages
English (en)
Inventor
RUPPRECHTER Alfred
Posch Christoph
Toll Hansjörg
Holzmann Johann
Fuchs Michael
Mayer Robert
LAMANNA William
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51210344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017000955(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of BR112017000955A2 publication Critical patent/BR112017000955A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/20—Post-translational modifications [PTMs] in chemical analysis of biological material formation of disulphide bridges

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção é dirigida a métodos para determinar a quantidade relativa de tnfr2:fc em ponte de dissulfeto incorreta em uma amostra de tnfr2:fc, uma proteína de fusão que é usada em uma variedade de aplicações terapêuticas. além disso, a invenção refere-se a um método para a purificação de tnfr2:fc usando o dito método para determinar a porcentagem de tnfr2:fc em ponte de dissulfeto incorreta, e para composições tnfr2:fc obtidas desse modo.
BR112017000955A 2014-07-18 2015-07-17 método para determinar tnfr2:fc, método de purificação de tnfr2:fc e composição de tnfr2:fc BR112017000955A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14177696.3A EP2975050B1 (en) 2014-07-18 2014-07-18 Quantification of misfolded TNFR2:Fc
PCT/EP2015/066385 WO2016009036A1 (en) 2014-07-18 2015-07-17 Quantification of misfolded tnfr2:fc

Publications (1)

Publication Number Publication Date
BR112017000955A2 true BR112017000955A2 (pt) 2018-01-16

Family

ID=51210344

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000955A BR112017000955A2 (pt) 2014-07-18 2015-07-17 método para determinar tnfr2:fc, método de purificação de tnfr2:fc e composição de tnfr2:fc

Country Status (10)

Country Link
US (2) US9598718B2 (pt)
EP (1) EP2975050B1 (pt)
KR (1) KR20170031145A (pt)
AU (1) AU2015289100B2 (pt)
BR (1) BR112017000955A2 (pt)
CA (1) CA2952342A1 (pt)
ES (1) ES2733298T3 (pt)
MX (1) MX2017000831A (pt)
RU (1) RU2698671C2 (pt)
WO (1) WO2016009036A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
CN114917185B (zh) 2016-10-21 2023-11-14 美国安进公司 药物配制品及其制备方法
WO2023053032A1 (en) * 2021-09-28 2023-04-06 Kashiv Biosciences, Llc An improved process for purification of fusion protein

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
AU2003234682A1 (en) * 2002-05-31 2003-12-19 Waters Investments Limited Destructible surfactants and uses thereof
CN100509847C (zh) 2003-08-01 2009-07-08 安美基公司 结晶肿瘤坏死因子受体2多肽
US7408030B2 (en) * 2005-01-13 2008-08-05 North Carolina State University Purification of immunoglobulins using affinity chromatography and peptide ligands
EA017152B1 (ru) * 2006-08-28 2012-10-30 Арес Трейдинг С.А. СПОСОБ ОЧИСТКИ Fc-СОДЕРЖАЩИХ БЕЛКОВ
WO2010002911A2 (en) * 2008-06-30 2010-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods and materials for monitoring myeloma using quantitative mass spetrometry
CA2797356C (en) 2010-04-26 2020-12-29 Novartis Ag Improved cell culture medium
AU2011246504B2 (en) 2010-04-26 2013-09-26 Novartis Ag Improved cell culture medium
CN102382190B (zh) 2010-09-01 2014-04-09 山东新时代药业有限公司 分离和去除TNFR-Fc融合蛋白中寡聚体的方法
AU2012220890A1 (en) * 2011-02-25 2013-08-29 Merck Sharp & Dohme Corp. Yeast strain for the production of proteins with modified O-glycosylation
US20140128577A1 (en) 2011-06-24 2014-05-08 Dr. Reddy's Laboratories Limited Purification of chimeric protein
US9279014B2 (en) 2011-08-17 2016-03-08 Ares Trading S.A. Methods for preparing an active TNFR-Fc fusion protein
JP2015533797A (ja) * 2012-09-11 2015-11-26 コヒラス・バイオサイエンシズ・インコーポレイテッド 高純度および優れた収率の正確に折り畳まれたエタネルセプト
WO2014102814A1 (en) 2012-12-31 2014-07-03 Intas Biopharmaceuticals Limited Process for the purification of fc fusion proteins
DK3611180T3 (da) * 2013-03-15 2022-02-28 Biomolecular Holdings Llc Hybrid immunoglobulin indeholdende ikke-peptidyl-binding

Also Published As

Publication number Publication date
RU2017102487A (ru) 2018-08-20
EP2975050A1 (en) 2016-01-20
AU2015289100A1 (en) 2017-01-12
EP2975050B1 (en) 2019-05-29
US9598718B2 (en) 2017-03-21
US9182410B1 (en) 2015-11-10
MX2017000831A (es) 2017-05-01
US20160017403A1 (en) 2016-01-21
AU2015289100B2 (en) 2019-08-15
KR20170031145A (ko) 2017-03-20
RU2017102487A3 (pt) 2018-10-03
WO2016009036A1 (en) 2016-01-21
RU2698671C2 (ru) 2019-08-28
ES2733298T3 (es) 2019-11-28
CA2952342A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
BR112018007017A2 (pt) polipeptídeos
CL2020003409A1 (es) Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154)
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
DK3019619T3 (da) Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
BR112017026330A2 (pt) molécula de ligação de lag-3 capaz de ligação tanto o lag-3 humano quanto ao lag-3 de macaco cynomolgus
BR112018000768A2 (pt) anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112017012615A2 (pt) composição e película de enrijecimento da pele, e, método para melhorar a aparência da pele.
EA201691974A1 (ru) Антитела против ox40 и способы их применения
CR20190330A (es) Anticuerpos anti-ox40 y sus usos
EA201591515A1 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение
BR112017027567A2 (pt) proteínas de fusão para inibir a angiogênese
EA201890080A1 (ru) Анализ модуляторов
EA201790273A1 (ru) Флагеллиновые композиции и их применение
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
EA201691541A1 (ru) Новые анти-baff антитела
CR20170262A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
BR112016023851A2 (pt) ?composição de revestimento de duas partes e método para revestir uma superfície?
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
EP3200582A4 (en) Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
BR112016029013A2 (pt) aperfeiçoamento em composição nasal e método de utilização do mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements